



## Millendo Therapeutics, Inc. to Present at the 18th Annual Needham Healthcare Conference

April 2, 2019

ANN ARBOR, Mich.--(BUSINESS WIRE)--Apr. 2, 2019-- [Millendo Therapeutics, Inc.](#) (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference in New York City on Tuesday, April 9, 2019 at 12:00 p.m. EST.

A live webcast of the presentation will be available on the Investors & Media section of Millendo's website at <http://investors.millendo.com>. A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.

### **About Millendo Therapeutics, Inc.**

Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing's syndrome. For more information, please visit [www.millendo.com](http://www.millendo.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190402005320/en/>

Source: Millendo Therapeutics, Inc.

### **Millendo Investor Contact:**

Stephanie Ascher  
Stern Investor Relations  
212-362-1200  
[stephanie@sternir.com](mailto:stephanie@sternir.com)

### **Millendo Media Contact:**

Betsy Yates  
MacDougall  
781-235-3094  
[byates@macbiocom.com](mailto:byates@macbiocom.com)